Spatial Markov transfer probability matrix. by Wenping Ning (19871091)

“…<div><p>Introduction</p><p>The apple industry is an essential industry to assist in rural revitalization. …”

Three-dimensional kernel density of APCA. by Wenping Ning (19871091)

“…<div><p>Introduction</p><p>The apple industry is an essential industry to assist in rural revitalization. …”

Flowchart of the study population. by Alejandro Rojas Chaves (20614814)

“…<div><p>Introduction</p><p>Recently, efforts to eliminate malaria have shifted focus from symptomatic cases alone to include asymptomatic carriers, who are now recognized as significant contributors to the disease’s transmission and control. …”

Summary of study participants. by Jesús Poch-Páez (21807825)

“…<div><p>Background</p><p>This study aimed to assess whether the expression of ACE2 and TMPRSS2 is associated with susceptibility to and severity of COVID-19 across age groups. …”

Participants’ characteristics. by Jesús Poch-Páez (21807825)

“…<div><p>Background</p><p>This study aimed to assess whether the expression of ACE2 and TMPRSS2 is associated with susceptibility to and severity of COVID-19 across age groups. …”

Sources of infection. by Jesús Poch-Páez (21807825)

“…<div><p>Background</p><p>This study aimed to assess whether the expression of ACE2 and TMPRSS2 is associated with susceptibility to and severity of COVID-19 across age groups. …”

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

“…<b>c</b> Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: <i>p</i> < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, <i>p</i> = 0.7096 vs control; +20 μg/mL, <i>p</i> = 0.0107 vs control; +200 μg/mL, <i>p</i> < 0.0001 vs control). …”

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

The original data for the figures. by Masashi Okawa (8951294)

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

The principle of operation of the TOPSIS technique. by Roman Vavrek (13200141)

Comparison of the selected multi-criteria methods. by Roman Vavrek (13200141)

Morphologic changes after dihydrotestosterone (DHT) treatment.1A: Diffuse lobular atrophy (20x). by Jinho Lee (587173)

Regression results of the different number of patents. by Pu Miao (12886949)

Territorial-administrative division of the Slovak Republic (districts). by Roman Vavrek (13200141)

A set of 5 criteria for the needs of multi-criteria evaluation–combination A. by Roman Vavrek (13200141)

Invention patent applications and grants in China. by Pu Miao (12886949)